admin

admin November 18, 2019

Phenocopy frontotemporal dementia (phFTD) shares core characteristics with behavioral variant frontotemporal dementia (bvFTD), yet without associated cognitive deficits and brain abnormalities on conventional magnetic resonance imaging (MRI), and without progression. Using advanced MRI techniques, we previously observed subtle structural and functional brain changes in phFTD similar to bvFTD.… Read More...

admin November 18, 2019

Objectives: To investigate the performance of substate classification of children with benign epilepsy with centrotemporal spikes (BECTS) by granger causality density (GCD) based support vector machine (SVM) model.

Methods: Forty-two children with BECTS (21 females, 21 males; mean age, 8.6 ± 1.96 years) were classified into interictal epileptic discharges (IEDs; 11 females, 10 males) and non-IEDs (10 females, 11 males) substates depending on presence of central-temporal spikes or not.… Read More...

Bon D. Ku November 18, 2019

American Journal of Alzheimer’s Disease &Other Dementias®, Ahead of Print.
Urinary Alzheimer-associated neural thread protein (AD7c-NTP) is a potential biomarker of Alzheimer disease (AD) or mild cognitive impairment (MCI). It is still unclear whether the urinary levels of AD7c-NTP are different between patients with amnestic MCI (aMCI) and nonamnestic MCI (naMCI).… Read More...

Fiore Manganelli, Silvia Parisi, Maria Nolano, Francesco Miceli, Stefano Tozza, Chiara Pisciotta, Rosa Iodice, Vincenzo Provitera, Rita Cicatiello, Stephan Zuchner, Maurizio Taglialatela, Tommaso Russo, Lucio Santoro November 17, 2019

Abstract

Background and aims

The development of patient‐specific induced pluripotent stem cells (iPSCs) offered interesting insights in modeling the pathogenesis of Charcot‐Marie‐Tooth (CMT) disease and thus we decided to explore the phenotypes of iPSCs derived from a single CMT patient carrying a mutant ATP1A1 allele (p.Pro600Ala).… Read More...

Holland C. Detke, Brian A. Millen, Qi Zhang, Karen Samaan, Jessica Ailani, David W. Dodick, Sheena K. Aurora November 17, 2019

Objective

To evaluate onset of effect of galcanezumab in patients with episodic migraine.

Background

Galcanezumab is a monoclonal antibody that binds to calcitonin gene‐related peptide and is indicated for preventive treatment of migraine.

Design/Methods

Data on the primary outcome measure were analyzed from 2 previously published double‐blind, Phase 3 studies (EVOLVE‐1 [N = 858] and EVOLVE‐2 [N = 915]) wherein adult patients with episodic migraine were randomized to receive monthly subcutaneous injections of galcanezumab 120 mg (with 240‐mg loading dose) or 240 mg or placebo for up to 6 months.… Read More...

Andoird App
Loading...